Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Oral medicine for treating cardio-cerebral vascular disease and preparation process thereof

A technology for cardiovascular and cerebrovascular diseases and pharmaceutical preparations, which is applied in cardiovascular system diseases, drug delivery, drug combination, etc. Low incidence, good drug effect, and the effect of reducing the number of times of medication

Inactive Publication Date: 2004-06-09
CHENGDU LIST PHARMA
View PDF0 Cites 54 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Although there are preparations such as breviscapine tablets and breviscapine injections on the market, they are all conventional (ordinary) preparations, requiring multiple doses per day, which is extremely inconvenient to use and poor patient compliance, making it difficult to achieve better treatment Purpose, at the same time, according to the knowledge of biopharmaceuticals, the blood drug concentration in the human body fluctuates greatly after repeated medication, leading to large adverse drug reactions or poor drug efficacy, and the human body's tolerance to drugs is poor or ineffective or even ineffective

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0024] The oral pharmaceutical preparation of the present invention is a slow-release tablet made of breviscapine as the main raw material and mixed with slow-release materials.

[0025] The composition and weight ratio of the 12-hour sustained-release tablet of the present invention (2 tablets on the day, in 1 tablet) are:

[0026] Breviscapine: 60mg

[0027] Diluent: 60mg

[0028] Filler: 50mg

[0029] Sustained release material: 25mg

[0030] The slow-release material in the present invention is: high-viscosity hypromellose 4000 which acts as a slow-release matrix.

[0031] The diluent of the present invention is: dextrin.

[0032] The filler described in the present invention is; lactose.

[0033] Concrete preparation method of the present invention and process step are as follows (in 1 piece):

[0034] A. Sieve and mix breviscapine 60mg, diluent 60mg, filler 50mg and slow-release material 25mg evenly;

[0035] B, the mixed medicated powder was mixed with 40% ethano...

Embodiment 2

[0040] The oral pharmaceutical preparation of the present invention is a slow-release tablet made of breviscapine as the main raw material and mixed with slow-release materials.

[0041] The composition and weight ratio of the 24-hour sustained-release tablet (once a day, calculated as 1 tablet) according to the present invention are: scutellarin: 120mg, dextrin: 75mg, lactose: 150mg, hypromellose Su 15000: 50mg.

[0042] Concrete preparation method of the present invention and process step are as follows (in 1 piece):

[0043] A. Sieve and mix breviscapine 120mg, dextrin 75mg, lactose 150mg and hypromellose (15000) 50mg in the above weight ratio;

[0044] B, the mixed medicated powder was mixed with 60% ethanol solution as binder for 12 minutes to make soft material;

[0045] C. Pass the soft material through a 16-mesh nylon sieve to granulate, dry at 60°C, take it out and dry it in the air, and after granulating with a 14-mesh wire sieve, add 4 mg of magnesium stearate as ...

Embodiment 3

[0049] The oral pharmaceutical preparation of the present invention is a slow-release tablet made of scutellarin as the main raw material and mixed with slow-release materials.

[0050] The composition and weight ratio of the sustained-release tablet (calculated as one tablet) of the present invention are: scutellarin: 80 mg, dextrin: 60 mg, lactose: 120 mg, hypromellose 15000: 30 mg.

[0051] Concrete preparation method of the present invention and process step are as follows (in 1 piece):

[0052] A. Sieve and mix breviscapine 80mg, dextrin 60mg, lactose 120mg and hypromellose (15000) 30mg in the above weight ratio;

[0053] B, the mixed medicated powder was mixed with 50% ethanol solution as binder for 15 minutes to make soft material;

[0054] C. Pass the soft material through a 16-mesh nylon sieve to granulate, dry at 60°C, take it out and dry it in the air, and after granulating with a 14-mesh wire sieve, add 3.8 mg of magnesium stearate as a lubricant to aid flow, and ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The present invention discloses a slowly-released oral medicine preparation which is made up by using breviscapine as main raw material and has the functions of promoting blood circulation and removing blood stasis, removing obstruction in the channels to relieve pain for curing angiocardiopathy and cerebrovascular disease with obvious therapeutic effect and its preparation method. Said slowly-released tablet (by one tablet) contains 60-120 mg of breviscapine, 20-75 mg of diluent, 50-150 mg of filling agent and 10-50 mg of slow release material. Said invention also provides its preparation method and concrete steps.

Description

Technical field: [0001] The present invention relates to a pharmaceutical preparation and a preparation method thereof, in particular to a slow-release oral pharmaceutical preparation made of breviscapine as the main raw material for treating cardiovascular and cerebrovascular diseases and having the functions of promoting blood circulation, removing blood stasis, dredging collaterals and relieving pain and its preparation method. Background technique: [0002] Breviscapine is a kind of total flavonoids extracted from Asteraceae plant, which mainly contains scutellarin, and its chemical name is: 4', 5, 6-trihydroxyflavone-7-0-glucuronic acid Glycoside, which is yellow powder, soluble in alkaline water, slightly soluble in methanol, insoluble in water, chloroform, etc. Breviscapine has the effects of promoting blood circulation, removing blood stasis, dredging collaterals and relieving pain, and can significantly improve cerebral blood circulation, increase cerebral blood fl...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K9/22A61K31/7048A61P9/10
Inventor 倪友洪曹勇张玲
Owner CHENGDU LIST PHARMA
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com